Labcorp Holdings Inc. $LH Shares Purchased by Tidal Investments LLC

Tidal Investments LLC boosted its position in shares of Labcorp Holdings Inc. (NYSE:LH) by 12.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 30,559 shares of the medical research company’s stock after purchasing an additional 3,372 shares during the quarter. Tidal Investments LLC’s holdings in Labcorp were worth $8,557,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Capital Analysts LLC raised its stake in shares of Labcorp by 0.5% during the 2nd quarter. Capital Analysts LLC now owns 15,250 shares of the medical research company’s stock worth $4,270,000 after buying an additional 79 shares during the last quarter. NorthRock Partners LLC boosted its position in shares of Labcorp by 6.7% in the 2nd quarter. NorthRock Partners LLC now owns 2,099 shares of the medical research company’s stock worth $588,000 after buying an additional 132 shares in the last quarter. NewEdge Advisors LLC grew its stake in Labcorp by 12.4% in the 2nd quarter. NewEdge Advisors LLC now owns 11,004 shares of the medical research company’s stock valued at $3,081,000 after acquiring an additional 1,210 shares during the last quarter. Squarepoint Ops LLC increased its holdings in Labcorp by 85.8% during the 2nd quarter. Squarepoint Ops LLC now owns 258,438 shares of the medical research company’s stock valued at $72,363,000 after acquiring an additional 119,373 shares in the last quarter. Finally, Baird Financial Group Inc. increased its holdings in Labcorp by 144.8% during the 2nd quarter. Baird Financial Group Inc. now owns 10,085 shares of the medical research company’s stock valued at $2,824,000 after acquiring an additional 5,966 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insider Transactions at Labcorp

In other news, EVP Kathryn W. Kyle sold 92 shares of the firm’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $26,329.48. Following the sale, the executive vice president owned 3,904 shares in the company, valued at $1,117,285.76. This trade represents a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Bryan T. Vaughn sold 234 shares of Labcorp stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the sale, the executive vice president directly owned 6,746 shares of the company’s stock, valued at approximately $1,930,637.74. This represents a 3.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,919 shares of company stock worth $2,826,593 in the last three months. 0.84% of the stock is currently owned by company insiders.

More Labcorp News

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reaffirmed its 2026 guidance of adjusted EPS of $18.10 to $18.55, broadly consistent with the analyst consensus of $18.32. Maintaining guidance supports confidence in near-term earnings visibility. Labcorp Holdings Reiterates 2026 Outlook, Issues Long-Term Guidance
• Positive Sentiment: The company issued a 2029 outlook calling for compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The targets imply sustained expansion beyond the current year and could support a higher long-term earnings outlook. Labcorp 2026 Investor Day Announcement
• Positive Sentiment: Labcorp plans to use artificial intelligence, specialty testing, scientific capabilities and global scale to drive growth. Management also emphasized strong cash-flow generation and disciplined capital deployment, which may improve shareholder returns if execution meets expectations. Labcorp Bets Big on AI and Specialty Testing
• Neutral Sentiment: The Investor Day transcript provided additional detail on Labcorp’s strategic priorities and long-term financial framework, but the benefits depend on successful implementation and investment in new technologies and testing capabilities. Labcorp Analyst and Investor Day Transcript
• Negative Sentiment: LH recently declined about 4.3% and underperformed peers, indicating that investors may have viewed the Investor Day information as insufficient to justify the stock’s elevated valuation or may have taken profits despite the favorable long-term targets. Labcorp Stock Heads Into the Open After a 4.3 Percent Slide

Labcorp Price Performance

NYSE:LH opened at $311.36 on Friday. The firm has a market cap of $25.25 billion, a price-to-earnings ratio of 25.75, a price-to-earnings-growth ratio of 1.77 and a beta of 0.88. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average is $310.39 and its two-hundred day moving average is $281.94. Labcorp Holdings Inc. has a 12-month low of $244.52 and a 12-month high of $341.80.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. The business had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Research analysts expect that Labcorp Holdings Inc. will post 18.32 EPS for the current year.

Labcorp Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 28th were paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, August 28th. Labcorp’s payout ratio is presently 23.82%.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. JPMorgan Chase & Co. raised their price objective on shares of Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. UBS Group lifted their price objective on Labcorp from $361.00 to $380.00 and gave the stock a “buy” rating in a research report on Friday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $306.00 target price on shares of Labcorp in a research note on Friday, July 31st. Finally, Weiss Ratings upgraded Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Labcorp presently has a consensus rating of “Moderate Buy” and an average target price of $336.36.

About Labcorp

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.